Cardiac disease and arrhythmogenesis: Mechanistic insights from mouse models  by Choy, Lois et al.
IJC Heart & Vasculature 12 (2016) 1–10
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureCardiac disease and arrhythmogenesis: Mechanistic insights from
mouse modelsLois Choy a, Jie Ming Yeo b, Vivian Tse c, Shing Po Chan a, Gary Tse a,⁎
a School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
b School of Medicine, Imperial College London, SW7 2AZ, UK
c Department of Physiology, McGill University, Canada⁎ Corresponding author.
E-mail address: gary.tse@doctors.org.uk (G. Tse).
http://dx.doi.org/10.1016/j.ijcha.2016.05.005
2352-9067/© 2016 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 8 March 2016
Accepted 2 May 2016
Available online 14 May 2016The mouse is the second mammalian species, after the human, in which substantial amount of the genomic in-
formation has been analyzed. With advances in transgenic technology, mutagenesis is now much easier to
carry out in mice. Consequently, an increasing number of transgenic mouse systems have been generated for
the study of cardiac arrhythmias in ion channelopathies and cardiomyopathies. Mouse hearts are also amenable
to physical manipulation such as coronary artery ligation and transverse aortic constriction to induce heart fail-
ure, radiofrequency ablation of the AV node to model complete AV block and even implantation of a miniature
pacemaker to induce cardiac dyssynchrony. Last but not least, pharmacological models, despite being simplistic,
have enabled us to understand the physiological mechanisms of arrhythmias and evaluate the anti-arrhythmic
properties of experimental agents, such as gap junction modulators, that may be exert therapeutic effects in
other cardiac diseases. In this article, we examine these in turn, demonstrating that primary inherited arrhythmic
syndromes are now recognized to bemore complex than abnormality in a particular ion channel, involving alter-
ations in gene expression and structural remodelling. Conversely, in cardiomyopathies and heart failure, muta-
tions in ion channels and proteins have been identiﬁed as underlying causes, and electrophysiological
remodelling are recognized pathological features. Transgenic techniques causing mutagenesis in mice are ex-
tremely powerful in dissecting the relative contributions of different genes play in producing disease phenotypes.
Mousemodels can serve as useful systems inwhich to explore howprotein defects contribute to arrhythmias and
direct future therapy.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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The mouse is the secondmammalian species, after the humans [12],
in which substantial amount of the genomic information has been ana-
lyzed [13]. With advances in transgenic technology [14], mutagenesis is
now much easier to carry out in mice [15]. Consequently, an increasing
number of transgenicmouse systems have been generated for the study
of cardiac arrhythmias [16,17]. Thesemodels can be loosely divided into
ion channelopathies with minimal structural abnormalities, and those
of structural heart disease. The former group includes catecholaminergic
polymorphic ventricular tachycardia (CPVT) [18], the long [19] and short
QT syndromes (LQTS and SQTS), and Brugada syndrome (BrS) [20]. The
latter group includes several types of cardiomyopathies, such as arrhyth-
mogenic right ventricular dysplasia (ARVD) [21], dilated cardiomyopathy
(DCM) [22] and hypertrophic cardiomyopathy (HCM) [23]. However,
now it is much clearer that structural alterations are found in ion chan-
nelopathies; for example, myocardial ﬁbrosis is observed in BrSland Ltd. This is an open access articl[24–26], DCM and non-compaction cardiomyopathy features are found
in cardiac ryanodine receptor 2 mutation that is classically observed in
CPVT [27]. Conversely, cardiomyopathy has been associated with ion
channel mutations, as exempliﬁed by sodium channel mutation in DCM
[28]. Thus, these categories inevitably contain some overlap. As previous-
ly suggested, a better classiﬁcation of cardiomyopathy includes additional
subtypes affecting the cytoskeleton, desmosome, sarcomere and ion
channels [29]. Some authors have asserted that this classiﬁcation is too
complex for clinical use, proposing instead a “MOGES” classiﬁcation
based on “morphofunctional phenotype (M), organ(s) involvement (O),
genetic inheritance pattern (G), etiological annotation (E) including ge-
netic defect or underlying disease/substrate, and the functional status
(S) of the disease” [30]. Atrialﬁbrillation is a particularly complex disease,
involving an interplay between electrical and structural remodelling, au-
tonomic imbalance, alterations in calcium handling and genetic factors
[31]. Mouse studies have illustrated the importance of abnormal metab-
olism in the initiation of paroxysmal atrial ﬁbrillation and its progression
to persistent and permanent forms [32], and shed light on the electro-
physiological abnormalities predisposing to arrhythmias [33], but will
not be discussed further in this review.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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human cardiovascular conditions and associated arrhythmic properties
[34]. Physicalmodels includemyocardial infarction produced by coronary
artery ligation [35], hypertrophy and heart failure by transverse aortic
constriction [36], complete AV block model by radiofrequency ablation
of the AV node [37] and cardiac dyssynchronymodel by implantation of
a miniature pacemaker tailored to mouse hearts [38]. In contrast, phar-
macological models include the use of cardiac glycosides [39], hypoxia
[40], myocardial sensitizers [41] such as chloroform [42,43] and alter-
ations in electrolyte concentrations, for example, potassium [44]. Cardi-
ac toxins such as ethanol [45] and doxorubicin [46] have been used for
modelling heart failure [47]. The different types of models are summa-
rized in Fig. 1. In the next section, the advantages and disadvantages of
mouse models, and comparisons between human cardiac physiology
and mouse cardiac physiology will be discussed. The current under-
standing of each pathology, focusing on how mouse models have
aided understanding, will then be reviewed in turn.
2. Advantages and disadvantages of mouse models
Several reasons justify the use of mice to study of human arrhythmia
conditions. Firstly, 99% of mouse genes have a homologue in the human
genome [13]. Secondly, both species have a similar set of ion channel
genes [48]. Thirdly, the vast majority of these ion channel genes have
nearly identical sequence homology in both species [49]. Fourthly,
these genes have similar expression patterns, and their protein products
show similar structural, electrophysiological [50] and pharmacological
properties [48]. Finally, the same mutation in ion channel genes can
often produce similar phenotypes in both species. For example, geneti-
cally engineered mice with altered potassium channel expression show
prolonged ventricular action potential durations (APDs), prolonged elec-
trocardiographic QT intervals and increased arrhythmogenicity, closely
recapitulating the ﬁndings in the corresponding human conditions
[51]. There are also advantages of using mice. The ﬁrst relates to their
vulnerability to arrhythmias. The mouse heart is electrically more stable
than the human heart because of its small size, and spontaneous ventric-
ular arrhythmias are therefore less likely to occur [49]. This means a
smaller number ofmice are lost due to unwanted lethal arrhythmias, po-
tentially saving costs. The second relates to the relative ease of deﬁbrilla-
tion. Arrhythmias are easier to reverse in mice than in larger species,
making them invaluable for the evaluation of the effectiveness of anti-
arrhythmic drugs. However, caution must be taken because efﬁcacy
could be overestimated.
3. Comparisons betweenhumanandmouse cardiac electrophysiology
Mouse hearts are similar to human hearts in many respects, making
them invaluable asmodel systems for the studyof humanarrhythmic syn-
dromes. Firstly, the SAandAVnodes aswell as theHis-Purkinje systemare
structurally similar [52]. Secondly, the samepatterns of depolarization andFig. 1. Genetic, physical and pharmacrepolarization are observed in both species, with depolarization spreading
from endocardium to epicardium and from apex to base, and repolariza-
tion from epicardium to endocardium and frombase to apex [53]. Thirdly,
the transmural conduction velocities (CVs) are nearly identical in mouse
and human hearts [53]. Fourthly, apex-base and endocardium–epicardi-
um repolarization gradients are present in both species [54]. Finally, the
upstroke of the action potential in both mice and humans is attributed
to INa, making mouse hearts especially suitable for studying changes in
CV [55]. Readers who are interested in the electrophysiological mecha-
nisms of arrhythmogenesis are directed to these review articles [56–58].
However, it must also be recognized thatmice do show some impor-
tant differences in their cardiac electrophysiology [51,53,59]. Firstly, the
basal heart rate in the mouse is around 600 bpm, which is ten times
greater than that observed in the human [60]. Secondly, the morpholo-
gy of the mouse and human ventricular action potentials is different,
with the mouse ventricular action potential having a shorter duration
and lacking a plateau phase [61]. This has been attributed to different
expression levels of repolarizing potassium channels. Thus, Ito is the
major repolarization current with IKr and IKs having a diminished role
in mice [62], whereas IKr and IKs are the major repolarization currents
in humans [63]. Additional differences betweenmouse and humanelec-
trophysiology lead to difﬁculties in extrapolating data obtained from
mice to humans and interpreting the mouse electrocardiogram [64].
Other species such as guinea pigs [65–71] and rabbits [72,73] may be
better models for studying cardiac repolarization, as their ion currents
are similar to those found used by human hearts.
The critical mass hypothesis posited that heart size must be sufﬁ-
ciently large to support ﬁbrillation [74]. Because the wavelength of the
excitation, given by ERP x CV, must be smaller than the available path
length to allow re-entry [75], mouse hearts were originally thought to
be too small to sustain re-entrant pathways. However, reconstruction
of activation pattern [64] and mapping studies [19,76,77] have both
shown that re-entry can take place. Bearing these limitations in mind,
mousemodels have provided signiﬁcant advances in our understanding
of cardiac electrophysiology. It is made possible by monophasic action
potential (MAP) and bipolar electrogram (BEG) techniques to examine
local activation and repolarization patterns [78–81]. Fig. 2 shows an ex-
perimental setup for recording left ventricular epicardial MAPs from
isolated, Langendorff-perfused mouse hearts during right ventricular
pacing. The study of congenital ion channelopathies has provided
much insights into the general mechanisms by which disturbances in
action potential conduction and repolarization generate arrhythmias,
whereas that of heart failure and atrial ﬁbrillation have identiﬁed path-
ological processes underlying disease progression with time and age
[82]. These conditions will be discussed in turn.
4. Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an
inherited, cardiac ion channelopathy characterized by adrenaline-ological models in mouse hearts.
Fig. 2. Experimental setup for Langendorff perfusion, which monophasic action potential
(MAP) recordings during simultaneous pacing.
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bidirectional ventricular tachycardia (VT), which is inducible by exer-
cise stress testing [84,85]. Other presentations include polymorphic VT
and survivors of cardiac arrest [85]. An autosomal dominant form,
CPVT1, was ﬁrst found to be associated with mutations in the gene
encoding for the cardiac ryanodine receptor 2 (RyR2), which releases
calcium from the sarcoplasmic reticulum [86]. To date, some 150 muta-
tions in RyR2 have been implicated in CPVT [85]. Recently, a large geno-
mic deletion of human cardiac RYR2 gene, resulting from in-frame
deletions of exon-3 (Ex3-del), has been detected in several, unrelated
families [27,87–89]. The proposed mechanism of arrhythmogenesis in
CPVT has traditionally been delayed afterdepolarization (DAD) phe-
nomena leading to triggered activity (Fig. 3) [90]. This has been attribut-
ed to a leaky RyR2 leading to calcium release [91]. However, this
mechanistic scheme is an inadequate for arrhythmias due to loss-of-
function RyR2 mutations, for which murine studies have provided
much insight into the underlying physiological mechanisms [92].
CPVT2, an autosomal recessive form, is associated with missense
mutations of the gene encoding for calsequestrin 2 (CASQ2), a
calcium-binding protein of the sarcoplasmic reticulum [93,94]. Affected
individuals were homozygous for the D307H missense mutation
[93,94]. Interestingly, three other missense mutations in CASQ2
have been described in particular severe forms of CPVT, with possible
autosomal dominant or oligogenic inheritance [95].
In mice, several gain-of-function mutations in RyR2 have been
generated, shedding light onto the molecular mechanisms of
arrhythmogenesis. Heterozygous knock-in mice carrying the RyR2
(R4496C)mutation shows increased calcium sensitivity of RyR2, leadingFig. 3. Afterdepolarization phenomena: early afterdepolarization (EAD) occurs early
(phase 2) or late (phase 3), and delayed afterdepolarization (DAD) occurs during phase
4 of the action potential. When sufﬁciently large, these can result in triggered activity.
Reproduced from Tse (2015) [58] with permission.to diastolic calcium release [96]. Interestingly, experiments in single cells
from this system showed that increasing the sarcoplasmic reticulum cal-
cium overload alone is sufﬁcient to induce DAD activity through activa-
tion of the sodium–calcium exchanger (NCX) [97]. This took place even
in an absence of beta adrenergic stimulation [97]. In homozygous
RyR2-P2328S mice, abnormal calcium handling has been associated
with reduced CVs, predisposing the hearts to spontaneous ventricular ar-
rhythmias [98]. Studies using isolated myocytes showed that the abnor-
mal functions of RyR2 have been rescued by increasing the afﬁnity of
calmodulin to RyR2, which reduced the frequency of DADs and triggered
activity [99]. In contrast, mouse models for loss-of-function RyR2
mutation can be exempliﬁed by RyR2-A4860G heterozygotes [92]. Isolat-
ed myocytes from these mice showed a reduced amplitude of calcium
release during systole, leading to calciumoverload of the sarcoplasmic re-
ticulum [92]. This in turn caused random bursts of prolonged calcium re-
lease, activation of NCXwith consequent early after-depolarization (EAD)
phenomena. Furthermore, heterozygous Ex3-del mice (Ex3-del+/−)
modelling the corresponding human condition failed to show susceptibil-
ity to CPVT [100]. Nevertheless, cardiac speciﬁc, conditional knockout of
the wild-type RyR2 allele in Ex3-del+/−mice led to bradycardia and sud-
den death [100], closely recapitulating the ﬁndings observed in humans.
This would suggest there are variations in the arrhythmic phenotype. Fi-
nally, genetically modiﬁed mice bearing CASQ2 mutation showed de-
creased refractoriness of the RyR leading to spontaneous diastolic
calcium release, and hence the development of DADs [101].
In summary, the above mouse models implicate abnormal calcium
handling as a predominant mechanism underlying arrhythmogenesis
in CPVT. This in turn results in an inward current by activation of the
NCX, and in turn to EADs or DADs, which can induce triggered activity.
Abnormal calcium handling may also lead to reduced CV of action po-
tential propagation, additionally serving as a substrate for circus re-
entry (Fig. 4).
5. Long QT syndromes (LQTS)
Long QT syndromes (LQTS) refers to a group of disorders character-
ized by a prolonged QT interval of ≥450 ms on the electrocardiogram
(ECG), with congenital or acquired causes. The underlying electrophys-
iology involves either reduced repolarizing currents or increased
depolarizing currents. Congenital LQTS has two hereditary variants: Ro-
mano–Ward syndrome is inherited in an autosomal dominant manner,
and Jervell and Lange–Nielsen (JLN) syndrome shows autosomal reces-
sive inheritance associated with congenital deafness [102]. Thirteen
LQTS subtypes have been identiﬁed thus far. LQTS 1 (KCNQ1), 2
(KCNH2), 5 (KCNE1), 6 (KCNE2), 7 (KCNJ2) and 13 (KCNJ5) are caused
by loss-of-functionmutations in genes encoding for the different potas-
sium channels. LQTS 3 (SCN5A) and 10 (SCN4B) are caused by gain-of-Fig. 4. Circus-type reentry requires a structural or functional obstacle (gray center) around
which an action potential can circulate.
Reproduced from Tse (2015) [58] with permission.
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(CACNA1C), called Timothy syndrome, is caused by gain-of-function
mutations in the L-type calcium channel. LQT 4 (ANKB), 9 (CAV3), 11
(AKAP9) and 12 (SNTA1) are caused by mutations in other supporting
proteins. Acquired causes of LQTS are muchmore common than congen-
ital syndromes. This is exempliﬁed by hypokalaemia, which is the most
common electrolyte abnormality encountered in clinical practice. A
mouse pharmacological model of experimental hypokalaemia has dem-
onstrated the following electrophysiological mechanisms: APDs are
prolonged, predisposing to EADs and therefore triggered activity (Fig. 5)
[44,103]. This prolongation preferentially occurs at the epicardium com-
pared to the endocardium, leading to a reversal of the transmural repolar-
ization gradient [44]. This in combinationwith reduced refractory periods
[104], produced a favourable substrate for re-entrant arrhythmias that
can readily be induced by programmed electrical stimulation. Moreover,
altered cardiac dynamics, particularly the onset of APD alternans, attrib-
uted to increased steepness of action potential restitution, also contribute
to re-entrant substrates (Fig. 6) [57,105]. It was shown that loss of gap
junction function paradoxically exerted anti-arrhythmic effects, by re-
versing changes in refractory periods despite leaving APD and CV restitu-
tion unaffected [103,105].Modulation of gap junctionsmay therefore be a
viable therapeutic strategy for anti-arrhythmic therapy [106–109].
6. Short QT syndromes (SQTS)
Short QT syndrome is a group of heterogeneous conditions character-
ized by an abbreviated QT interval (QTc b 350ms). It causes an increased
risk of atrial and ventricular arrhythmias, in particular ventricular ﬁbrilla-
tion, thereby predisposing to sudden cardiac death. The shortening of QT
interval could be contributed by an increased activity of repolarizing cur-
rents, or reduced activity of depolarizing currents. Six genetic subtypes of
SQTS have been identiﬁed thus far. Gain-of-functionmutations in the po-
tassium channel genes, KCNH2, KCNQ1 [110,111] and KCNJ2 [112] are
found in SQT1, 2 and 3. By contrast, loss-of-function mutations in L-type
calcium channel subunits, CACNA1C, CACNB2 and CACNA2D1, are found
in SQT4, 5 and 6, respectively [113]. Interestingly, altered cardiac me-
tabolism can also lead to a SQT phenotype, as exempliﬁed bymice treat-
ed with mildronate, which resulted in low carnitine and shortened QT
intervals [114]. The common electrophysiological abnormality involves
shortened APD, which reduces the excitation wavelength and thereby
predisposing to circus-type re-entry [58]. Unlike the long QT syn-
dromes, abnormal APD restitution leading to alternans formation,
which involves APD prolongation, is unlikely to be a contributing factor
in arrhythmogenesis [57].Fig. 5. Hypokalaemia prolongs APDs, which predisposes to triggered activity (left). This AP p
programmed electrical stimulation can reliably provoke ventricular arrhythmias (right).
Traces reproduced from Tse et al. (2016) [103] with permission.7. Brugada syndrome (BrS)
In Brugada syndrome, there is loss-of-function mutations in the
SCN5A gene, predisposing affected individuals to ventricular arrhythmias
and sudden death [115]. There has been considerable debate on the
mechanisms of arrhythmogenesis in BrS. The leading theories are the de-
polarization and repolarization hypotheses [116]. The depolarization hy-
pothesis proposes that mild structural abnormalities leading to
conduction disturbances, which would predispose to circus-type re-
entry. By contrast, the repolarization hypothesis depends on transmural
dispersion of repolarization between endocardium and epicardium in
the right ventricular outﬂow tract (RVOT). Experiments performed on
mouse models have shed some light on the underlying mechanisms.
Thus, heterozygous targeted disruption of Scn5a (Scn5a+/−) mice
showed conduction abnormalities associated with ﬁbrosis in the right
ventricle [117]. Adult mice heterozygous for a mutation associated
with BrS (Scn5a1798insD/+) showed reduced CVs in the RVOT [118], and
those possessing the SCN5aG1408R mutation showed slowed conduction,
shortened APDs despite prolonged refractory periods associated with
mild interstitial ﬁbrosis [119]. This would suggest contributions from
both depolarization and repolarization abnormalities to the arrhythmic
phenotype. Reduced sodium current can also arise from dysfunction of
other proteins, such as the desmosomal component plakophilin-2. Pa-
tients with missense mutations of this protein show a reduced number
of sodium channels at the intercalated disc associated with a Brugada
phenotype. Interestingly, mouse hearts with plakophilin-2missensemu-
tations show a phenotype that is more consistent with ARVD, as de-
scribed below [120]. This in turn suggests that although both ARVD
and BrS are primarily right ventricular diseases, there is a phenotypical
spectrum with decreasing severity of structural abnormalities away
from ARVD towards BrS.
8. Arrhythmogenic right ventricular dysplasia (ARVD)
Arrhythmogenic right ventricular dysplasia (ARVD) is a primary car-
diomyopathy characterized by ﬁbro-fatty replacement of the right ven-
tricular myocardium, predisposing affected individuals, particularly in
young adults and athletes, to ventricular arrhythmias and sudden cardi-
ac death [121]. The disease progresses to ventricular wall thinning and
development of aneurysms [122]. Approximately 50% of the patients
have defects in their desmosomal components [123]. Desmosomes con-
sist of cadherins, armadillo proteins (which include plakoglobin and
plakophilin 2, PKP2) and desmoplakin, which links this complex to des-
min in the intermediate ﬁlament [124]. The culprits for the remainingrolongation and reduced refractoriness together form a re-entrant substrate. The use of
Fig. 6. Hypokalaemia exacerbates APD alternans at fast heart rates (left) due to steep APD restitution (right).
Traces reproduced from Tse et al. (2016) [105] with permission.
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different proteins affected. Inhibitor of apoptosis-stimulating protein of
p53 (iASPP) is a protein expressed in intercalated discs, interactingwith
desmoplakin [125] and its deﬁciency was shown to induce features of
ARVD in mice [125]. Rho-kinase inhibition in the developing mouse
heart (SM22α-restricted) show similar physical ﬁndings [126]. Al-
though traditionally recognized as a predominant right ventricular dis-
ease, left-dominant and biventricular involvement has been described
[127]. Mouse models have advanced our understanding, in particular
implicating desmoplakin deﬁciency as a cause in left-ventricular and
biventricular dominant forms [128], supporting similar ﬁndings ob-
served in humans [129].
In humans, recent studies have implicated exercise and endurance
training as precipitants or triggers of arrhythmias [130,131]. Heterozy-
gous plakoglobin-deﬁcient mice showed accelerated development of
structural abnormalities and arrhythmias following endurance training
[132]. Moreover, missense mutation of the plakophilin-2 gene (PKP2)
demonstrated right ventricular systolic dysfunction and regional wall
motional abnormalities on cardiacmagnetic resonance imaging in exer-
cise trained but not sedentary mice [120]. This would suggest an
unmasking of an otherwise quiescent arrhythmic phenotype inducible
by exercise. Together, both clinical andmouse studies provide evidence
that exercise restriction prevent the occurrence of ventricular arrhyth-
mias in ARVD patients.
9. Dilated cardiomyopathy (DCM)
Dilated cardiomyopathy is a type of primary cardiac muscle disorder
characterized by increased ventricular mass and dilatation associated
with impairedmechanical function [133]. It predisposes affected individ-
uals to ventricular arrhythmias and sudden death. Only 30% of DCM
cases are familial [133]. To date, two X-linked and 31 autosomal genetic
mutations have been identiﬁed as the causes of DCM [134,135]. Often
these are proteins that are responsible formaintaining structural integri-
ty of the cardiomyocyte, such as myosin heavy chain (MHC), myosin-
binding protein C, alpha tropomyosin, and titin, which is the largest pro-
tein identiﬁed thus far. Other causes include environmental factors, suchas viral infections by enteroviruses and adenovirus, which result inmyo-
carditis and subsequently DCM [136]. Mousemodels have been useful in
elucidating the ion channel abnormalities and electrophysiological
mechanisms underlying arrhythmogenesis in this condition. For exam-
ple, homozygous mutant mice expressing a truncated form of myosin-
binding protein C (MyBP-Ct/t) develop severe dilated cardiomyopathy,
exhibited extensive cardiac ﬁbrosis associatedwith inducible ventricular
tachycardia (AT) despite surprisingly normal conduction and refractori-
ness [137].
Interestingly, DCM has been associated with reduced SCN5a expres-
sion [138]. Thus, in transgenic mice that ectopically express the tran-
scriptional repressor Snail, there was a severe DCM phenotype together
with reduced sodium current and conduction slowing without changes
in intercellular coupling. The mechanism of arrhythmia here may be
circus-type re-entry, which requires conduction slowing. Moreover,
mice with the D1275N mutation in SCN5a showed features of DCM, re-
duced CVs, heart block and ventricular arrhythmias [139]. Mice with a
deletion mutation ΔK210 in cardiac troponin T had DCM, APD prolonga-
tion secondary to reductions in transient outward (Ito) and ultrarapid de-
layed rectiﬁer K+ (IKur) currents [140]. This predisposed them to both
early and delayed afterdepolarization phenomena and therefore trig-
gered activity. A signiﬁcant ﬁnding is that potassium channel downregu-
lation was observed even when there was no evidence of heart failure
[140]. This thereby implicates ion channel remodelling as an important
mechanism for arrhythmogenesis in DCM, and already takes place before
additional electrophysiological abnormalities associated with heart fail-
ure, such as NCX upregulation, become apparent. Together, these ﬁnd-
ings in mice are consistent with those in humans, where SCN5a
mutations have also been implicated in the pathogenesis of DCM [141].
In other mouse model, where mice overexpressing dominant-
negative neuron-restrictive silencer factor (NRSF), a transcriptional reg-
ulator ofmyosin, developed aDCMphenotype [142]. Thesemice showed
increased expression of If and ICa,T, which are usually expressed in pace-
maker cells, suggesting that increased automaticity may also be an un-
derlying arrhythmogenic mechanism in DCM. In cardiomyocytes, the
cytoskeleton is in close association with the nuclear envelope, aided by
inner nuclear membrane proteins called lamins. Heterozygous lamin
6 L. Choy et al. / IJC Heart & Vasculature 12 (2016) 1–10knockout (Lmna+/−) mice showed DCM phenotype associated with in-
creased susceptibility to AV nodal disease aswell as ventricular tachycar-
dia [143].
10. Hypertrophic cardiomyopathy (HCM)
Hypertrophic cardiomyopathy is the commonest inherited cardiac
disease characterized by anon-dilated, hypertrophied left ventriclewith-
out other causes of hypertrophy, such as storage, inﬁltrative disease or
pressure overload, being observed [144]. Its genetics are less heteroge-
neous than DCM, as mutations in the genes that encode for the myosin
heavy chain, myosin binding protein C and troponin T are responsible
for about 75% of all inherited HCMs [145]. Heterozygous MyBP-Ct/+
mice showed a mild HCM and inducible ventricular tachycardia after
pharmacological stress with isoproterenol [137]. The duration of the VT
is less than the homozygousMyBP-Ct/t mice showing a severe DCM phe-
notype described above. Like DCM, in mice bearing the MHC mutation
(MHC403/+), it is the degree of hypertrophy, but not the extent or loca-
tion of myocardial disarray and ventricular ﬁbrosis, that correlated
with increased arrhythmogenicity [146]. Altered calcium sensing of the
myoﬁlament caused by troponin Tmutation resulted in HCM, shortened
ventricular effective refractory periods, increased dispersion of CVs and
increased APD alternans, all of which would predispose to re-entry
[147]. Moreover, mice with the cardiac troponin T I79N mutation
showed APD shortening and increased diastolic calcium release in the
presence of stress [148]. This could potentially result in DAD-induced
triggered activity, but remains to be studied in the future. Since ion chan-
nels can be abnormal in cardiomyopathies, they are potential targets for
therapy. For example, inhibitor of the late sodium current reversed by
mechanical and electrical dysfunction in HCM patients [149]. Mouse
models are therefore an attractive system in which to examine the ther-
apeutic effects of experimental drugs.
11. Heart failure
Heart failure is a signiﬁcant burden on our healthcare system, and
represents a common pathway of many aetiologies with an abysmal
clinical outcome [150]. It is characterized by structural abnormalities
of left ventricular dysfunction and dilatation, a compensatory rise in
systemic vascular resistance secondary to activation of neurohumoral
pathways [151], inﬂammation and metabolic adaptations to substrate
utilization [152]. The net effect is comprised cardiac contractility and
the inability to meet metabolic demands of peripheral tissues [153].
Cardiac dyssynchrony is a feature observed in heart failure, referring
to the disruption in both temporal and mechanical coordination be-
tween the contractive motions of different cardiac compartments. It
can be divided into atrioventricular, interventricular and intraventricu-
lar dyssynchrony.
The commonest heart failure model involves surgery intervention.
Generation of these models allow the different stages of heart failure
to be examined. Coronary artery ligation mimics myocardial infarction
[35,154], producing scarring of the myocardium followed by dilatation
of the ventricle. Novelsmethods of coronary artery ligation have recent-
ly been devised to model ischaemia-reperfusion [155,156], which
would be ideal for studying arrhythmias associated with this phenome-
non. In contrast, transverse aortic banding simulating pressure overload
from aortic stenosis or hypertension triggers hypertrophic response to
that similarly observed in humans [36,157]. Non-invasive imaging mo-
dalities such as strain-based modelling revealed areas of dyssynchrony
when there is no overt heart failure [158]. This supports the notion
that regional, as opposed to global, stress is induced by increased
afterload. The risk of ventricular arrhythmias is reducedwhen intraven-
tricular dyssynchrony improves in humans [159]. Mouse models will
prove useful to examine whether resynchronization of the failing
heart can lower arrhythmic risk. Genetic models have allowed the in-
vestigation of the roles of each gene in heart failure and determineswhether particular alterations of gene expression represent adaptive
or maladaptive responses [160,161]. Mutagenesis has been coupled
with coronary artery ligation techniques to examine the propensity to
arrhythmias. Thus, toll-like receptor 2 deﬁciency confers a protective ef-
fect against ventricular arrhythmias and reduces infarct size [162],
whereas cardiac knockout of mitochondrial uncoupling protein 3
shows poorer ventricular function and larger infarct size compared to
wild-type [163].
12. AV block
AV block refers to a group of disorders characterized by partial or
complete interruption of impulse transmission from the atria to the
ventricles. Depending on the extent of impulse interruption, it can be
classiﬁed into ﬁrst, second and third-degree, each with characteristic
appearance on the electrocardiogram. Approximately 50% of patients
with AV block have idiopathic ﬁbrosis and sclerosis of the conduction
system, 40% have ischaemic heart disease and the remaining minority
of cases can be attributed to valvular disease, increased vagal tone and
congenital bradycardia syndromes [164,165]. This condition can also
be caused by drugs, such as ﬁngolimod, pro-drug of a S1P-R modulator
licensed for multiple sclerosis [166]. Patients suffering from complete
atrioventricular block (CAVB) have an increased risk of sudden cardiac
death, potentially from QT prolongation and VT. Mouse models have
providedmuch insight of the electrophysiologicalmechanisms underly-
ing idiopathic AV block. It is now recognized that several proteins are re-
sponsible for the maintenance of AV conduction [167], such as T-type
calcium channels [168], L-type calcium channels [169], HCN channels
[170], and Sphingosine-1-phosphate receptor [171].
Micewith radiofrequency ablation of the AV node exhibited electro-
physiological modelling preceded structural remodelling, which were
associated with increased QT intervals and occurrence of polymorphic
VT [172]. Thus, Kv4.2 channels were downregulated with a consequent
reduction in the transient outward potassium current. These changes
were followed by biventricular hypertrophy and heart failure, as
reﬂected in transcriptional changes such as rise in α-actin, β-MHC and
B-type natriuretic peptide and fall in SERCA2 expression. Transgenic
mousemodels have also provided additional insight.Micewith deletion
of Cav3.1, which encodes for the α-subunit of the T-type calcium chan-
nel, was used in combination with radiofrequency AV node ablation
[173]. These mice showed hypertrophic remodeling after AV block and
were more prone to bradycardia-related ventricular arrhythmias.
Current treatment of AV block is by pacemaker implantation. With
consideration of the shortcomings of electronic pacemakers, genetic
manipulation of speciﬁc ion channels for biological pacemaker develop-
ment has been an area of intense research. Thus, non-viral gene transfer
with poloxamine nanosphere as the gene delivery system was used to
induce overexpression of the pacemaker current-generating channel
HCN2andβ2-adrenergic receptor (ADRB2),with the generation of func-
tional biological pacemakers and improvement in life expectancy of
mice with CAVB [37]. Recently, a S1P3 receptor antagonist (SPM-354)
was found to restore sinus rhythm and reverse CAVB [174]. Stem cell
therapy has also demonstrated promising results. Recently, brown adi-
pose tissue (BAT)-derived cells were injected intramyocardially around
the AV node, which full or partial recovery to sinus rhythm or second
degree 2:1 block [175].
13. Conclusion
This article reviewed the different genetic and physical models of
cardiovascular diseases, and explored howmousemodels have contrib-
uted to our understanding of arrhythmogenesis in these conditions [1–
9]. Primary inherited arrhythmic syndromes are now recognized to be
more complex than abnormality in a particular ion channel, involving
alterations in gene expression and structural remodelling [10,11]. Con-
versely, in cardiomyopathies and heart failure, mutations in ion
7L. Choy et al. / IJC Heart & Vasculature 12 (2016) 1–10channels and proteins have been identiﬁed as underlying causes, and
electrophysiological remodelling are recognized pathological features.
Transgenic techniques causingmutagenesis inmice are extremely pow-
erful in dissecting the relative contributions of different genes play in
producing disease phenotypes. The importance of translational research
cannot be overstated. As previously suggested, a better classiﬁcation is
myocardial disease involving abnormalities in one of the following cel-
lular components: cytoskeleton, desmosome, sarcomere and ion chan-
nels [29]. Overlap syndromes between different cardiomyopathies are
now increasing recognized but are nevertheless uncommon in humans,
and indeed rarer than individual cardiomyopathy occurring in isolation.
Thus, overlapping features between DCM and HCM, ARVD and HCM,
ARVD and DCM, and post-partum cardiomyopathy (PPCM) and ARVD
[176] have all been described. Mouse models can serve as useful sys-
tems inwhich to explore how protein defects contribute to arrhythmias
and direct future therapy.
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